Genelux corporationGNLX.US Overview

US StockHealthcare

(No presentation for GNLX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

GNLX Overall Performance

GNLX AI Analysis & Strategy

GNLX Recent Performance

-0.34%

Genelux corporation

1.30%

Avg of Sector

0.61%

S&P500

GNLX PowerScanner

GNLX Key Information

GNLX Valuation Metrics

GNLX Earnings Table

GNLX Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.